Neuroimmunological diseases: update

Research output: Contribution to journalReview article


During the past 10 to 20 years, disease modifying drugs have been introduced into clinical practice relating to neuroimmunological diseases such as multiple sclerosis, myasthenia gravis, and Guillain-Barré syndrome. Based on the mechanism of each disease, therapies are currently being developed that target crucial molecules involved in the disease process. Monoclonal antibodies, such as natalizumab against VLA-4 and alemtuzumab against CD52 antibody, have been found to be very effective for reducing relapse rates and for preventing disease progression in multiple sclerosis. However, molecular-targeted therapy may disrupt the immune balance of patients and unexpectedly induce other autoimmune diseases or opportunistic infections. Therefore, to overcome intractable neuroimmunological diseases utilizing molecular-targeted therapies, future research needs deeper insights into the mechanism of each disease along with close observations of clinical courses.

Original languageEnglish
Pages (from-to)1039-1048
Number of pages10
JournalNippon rinsho. Japanese journal of clinical medicine
Issue number6
Publication statusPublished - Jun 2008


All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this